Dren Bio raises $350 million to advance dibotatug in cytotoxic T-cell lymphoma and large granular lymphocytic leukemia and expand its antibody pipeline.
Written By: Creola Gonsalves, MS Biotech
Reviewed By: Pharmacally Editorial Team
Dren Bio has closed an oversubscribed $350 million private financing to advance dibotatug (DR-01), its investigational antibody targeting CD94, toward potential commercialization and accelerate development of its broader therapeutic pipeline.
The capital will support continued clinical development, planned regulatory submission and commercial launch preparations for dibotatug, which is being evaluated in cytotoxic T-cell lymphoma (CTL) and large granular lymphocytic leukemia (LGLL). The announcement also signals Dren Bio’s intention to expand its lead programme into additional indications while continuing to develop therapies through its proprietary antibody technology platform.
Dibotatug Development Anchors the Financing
Dibotatug is a fully human monoclonal antibody designed to target CD94 and selectively deplete pathogenic cytotoxic cells while preserving the broader immune system. Dren Bio is developing the investigational therapy for rare hematologic malignancies and other disorders involving pathogenic immune cells.
CTL encompasses rare, aggressive blood cancers associated with poor prognosis, while LGLL is a chronic hematologic malignancy that can cause severe neutropenia, anemia and transfusion dependence. Both indications have substantial unmet medical needs and lack approved therapies for the diseases targeted by dibotatug, according to the company.
Dren Bio reported that more than 300 patients had been dosed in the Phase 1/2 clinical programme evaluating dibotatug in CTL and LGLL. The company also described maturing data showing high overall and complete response rates among patients with relapsed or refractory disease, alongside a favourable safety and tolerability profile. Clinical findings have been presented at scientific meetings, including those of the American Society of Hematology, European Hematology Association and Society of Hematologic Oncology.
However, the financing announcement does not provide the numerical response rates, follow-up durations or detailed adverse-event data needed to independently assess the magnitude and durability of benefit. The reported findings therefore provide clinical context for the financing but should not be interpreted as establishing definitive efficacy or a favourable benefit-risk profile.
The company intends to use the new capital to continue late-stage development and prepare for regulatory submission and a planned commercial launch. These remain development objectives rather than confirmed regulatory outcomes.
Funding Also Supports Broader Pipeline Development
Beyond dibotatug, Dren Bio plans to expand the antibody into additional indications and accelerate programmes across oncology and autoimmune diseases. The company is also developing candidates using its Targeted Myeloid Engager and Phagocytosis Platform, a separate multispecific antibody technology designed to direct myeloid cells towards the depletion of targeted pathogenic cells and other disease-causing agents.
The platform supports Dren Bio’s broader strategy of developing antibody-based treatments across oncology, immunology and neurology. Its programmes represent additional development opportunities, although their eventual clinical and commercial value remains to be established.
The financing was co-led by Juvia Group and Lightspeed Venture Partners. New participating investors included Mirae Asset Capital Life Science, General Catalyst, Cormorant Asset Management and OrbiMed. Existing investors included 8VC, SR One, Taiho Ventures, Mission BioCapital, HBM Healthcare Investments, BVF Partners, Aisling Capital and ArrowMark Partners.
In connection with the financing, Sujal Shah, co-founder and managing director at Juvia Group, and Shelley Chu, MD, PhD, partner at Lightspeed Venture Partners, joined Dren Bio’s Board of Directors.
What the Financing Signals
The $350 million raise gives Dren Bio substantial capital to pursue its lead programme while investing in additional antibody-based therapies. Its significance lies in the company’s stated ambition to move dibotatug towards regulatory submission and potential commercialization while maintaining investment in its wider pipeline.
The next important measures of progress will be the availability of detailed clinical results, the durability of responses, the safety profile with longer follow-up and the clarity of the regulatory pathway. Until these elements are established, the financing should be viewed as support for continued development rather than evidence of future approval or commercial success.
Reference
Dren Bio Announces $350 Million Financing to Advance Dibotatug Toward Commercialization and Accelerate Development of Its Broader Pipeline, Dren Bio, 29 October 2026
About the Writer
Creola Gonsalves (Linkedin) is an M.S. Biotechnology postgraduate with a strong interest in clinical research, evidence interpretation, and healthcare writing, with a focus on translating life-science knowledge into meaningful real-world insights.
She is trained in Good Clinical Practice (GCP), clinical research principles, and critical interpretation of randomized clinical trials, with certifications from NIH and Stanford University.
Her research background in biotechnological applications and microbial research strengthens her ability to understand scientific evidence and develop clear, accurate, and research-driven healthcare content.